Skip to main content

Cerebral Aneurysm

0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Stryker
StrykerCA - San Jose
2 programs
Coil Embolization with larger Diameter CoilsN/A1 trial
Surpass Flow DiverterN/A1 trial
Active Trials
NCT01655784Completed651Est. Feb 2024
NCT02281721Terminated150Est. Dec 2019
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Heparin SodiumN/A1 trial
Active Trials
NCT03306836Unknown408Est. Aug 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UNION therapeuticsHeparin Sodium
StrykerSurpass Flow Diverter
StrykerCoil Embolization with larger Diameter Coils

Clinical Trials (3)

Total enrollment: 1,209 patients across 3 trials

Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2

Start: Sep 2016Est. completion: Aug 2021408 patients
N/AUnknown
NCT02281721StrykerSurpass Flow Diverter

Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection

Start: Mar 2015Est. completion: Dec 2019150 patients
N/ATerminated
NCT01655784StrykerCoil Embolization with larger Diameter Coils

Framing Eighteen Coils in Cerebral Aneurysms Trial

Start: Dec 2012Est. completion: Feb 2024651 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.